Human TWEAK/TNFSF12 Biotinylated Antibody

Antigen Affinity-purified Polyclonal Goat IgG
Catalog Number: BAF1090

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human TWEAK/TNFSF12 in ELISAs and Western blots. In sandwich immunoassays, less than 15% cross-reactivity with recombinant mouse TWEAK is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	*E. coli*-derived recombinant human TWEAK/TNFSF12 Arg93-His249 Accession # Q4ACW9
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

APPLICATIONS

Please Note: *Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.*

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW)
Immunocytochemistry	5-15 µg/mL	See Below
Human TWEAK/TNFSF12 Sandwich Immunoassay		**Reagent**
ELISA Capture	2-8 µg/mL	Human TWEAK/TNFSF12 Antibody (Catalog # MAB1090)
ELISA Detection	0.1-0.4 µg/mL	Human TWEAK/TNFSF12 Biotinylated Antibody (Catalog # BAF1090)
Standard		Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW)

DATA

Immunocytochemistry



TWEAK/TNFSF12 in human PBMCs. TWEAK/TNFSF12 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human TWEAK/TNFSF12 Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF1090) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Streptavidin (red; Catalog # NL999) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane and cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Use a manual defrost freezer and avoid repeated freeze-thaw cycles.** ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956

Human TWEAK/TNFSF12 Biotinylated Antibody

Antigen Affinity-purified Polyclonal Goat IgG
Catalog Number: BAF1090

BACKGROUND

TWEAK is a type II transmembrane protein belonging to the TNF superfamily (1). It contains a short cytoplasmic domain (amino acids (aa) 1-18), the transmembrane domain (aa 19-42) and an extracellular domain (aa 43-249). The extracellular domains of human and murine TWEAK share 89% aa sequence identity. A soluble form of TWEAK is generated from the membrane-associated molecules by proteolytic cleavage after Arg 93 suggesting that TWEAK may have long-range effects. TWEAK is expressed widely in many tissues and cells. At least two receptors that bind TWEAK have been identified (2-4). Death Receptor 3 (DR3), also known as TNFRSF12, Apo-3, LARD, WSL-1, or TRAMP, is a TNF receptor superfamily member that is expressed predominantly in tissues with high lymphocyte content (2). It has been suggested that induction of cell death by TWEAK-DR3 interaction involves the activation of NF-κB. In cells that lack DR3, alternate pathways of TWEAK-induced cell death mediated by receptors distinct from DR3 have been suggested (5, 6). TWEAK receptor (TWEAKR, alternatively known as FN14), is a novel TNF receptor superfamily member that also binds TWEAK (3, 4). It is a mitogen-inducible gene that is expressed in fibroblasts, hepetocellular carcinomas and endothelial cells. TWEAK-TWEAKR interaction has been shown to play a role in endothelial cell growth and migration. This effect of TWEAK is not mediated by an up-regulation of VEGF (7).

References:

1. Chicheportiche, Y. *et al.* (1997) J. Biol Chem. **272**:32401.
2. Marsters, S. *et al.* (1998) Current Biol. **8**:525.
3. Wiley, S.R. *et al.* (2001) Immunity, **15**:837.
4. Feng, S-L.Y. *et al.* (2000) Am J. Path. **156**:1253.
5. Nakayama, M. *et al.* (2002) J. Immunol. **168**:734.
6. Schneider, P. *et al.* (1999) Eur. J. Immunol., **29**:1785.
7. Lynch, C. *et al.* (1998) J. Biol. Chem. **274**:8455.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956